Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, 2-period, 2-sequence Study to Evaluate the Single-dose Pharmacokinetics of Milademetan When Administered Alone or Concomitantly With Itraconazole or Posaconazole in Healthy Subjects

Trial Profile

An Open-label, Randomized, 2-period, 2-sequence Study to Evaluate the Single-dose Pharmacokinetics of Milademetan When Administered Alone or Concomitantly With Itraconazole or Posaconazole in Healthy Subjects

Completed
Phase of Trial: Phase 0

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs Milademetan (Primary) ; Itraconazole; Posaconazole
  • Indications Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 09 Nov 2018 Status changed from recruiting to completed.
    • 10 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top